Mirnow revolutionizes cancer diagnostics using a two-tier multi-omic approach—first analyzing blood metabolite signatures, then microRNAs—to detect cancer stages with exceptional accuracy. Deep learning enhances sensitivity, pushing beyond the limitations of traditional DNA-based detection.
